UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review

Expert opinion on therapeutic patents, 2020-01, Vol.30 (1), p.27-38

2020

Volltextzugriff (PDF)

Enhancing fatigue properties of styrene butadiene rubber composites by improving interface adhesion between coated aramid fibers and matrix

Composites. Part B, Engineering, 2019-09, Vol.172, p.485-495

2019

Volltextzugriff (PDF)

Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents

European journal of medicinal chemistry, 2019-02, Vol.164, p.352-365

2019

Volltextzugriff (PDF)

HWL‐088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice

British journal of pharmacology, 2020-05, Vol.177 (10), p.2286-2302

2020

Volltextzugriff (PDF)

Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ

European journal of medicinal chemistry, 2018-11, Vol.159, p.267-276

2018

Volltextzugriff (PDF)

Reinforcing effect of aramid fibers on fatigue behavior of SBR/aramid fiber composites

Polymer testing, 2019-12, Vol.80, p.106092, Article 106092

2019

Volltextzugriff (PDF)

Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome

European journal of medicinal chemistry, 2021-12, Vol.225, p.113807-113807, Article 113807

2021

Volltextzugriff (PDF)

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

Bioorganic & medicinal chemistry, 2022-02, Vol.56, p.116615-116615, Article 116615

2022

Volltextzugriff (PDF)

ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis

Pharmacological research, 2020-09, Vol.159, p.105035-105035, Article 105035

2020

Volltextzugriff (PDF)

A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice

Pharmacological research, 2020-03, Vol.153, p.104679-104679, Article 104679

2020

Volltextzugriff (PDF)

Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice

Biochimica et biophysica acta. Molecular basis of disease, 2022-12, Vol.1868 (12), p.166556, Article 166556

2022

Volltextzugriff (PDF)

Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis

European journal of pharmacology, 2020-09, Vol.882, p.173300-173300, Article 173300

2020

Volltextzugriff (PDF)

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

European journal of medicinal chemistry, 2021-02, Vol.211, p.113106, Article 113106

2021

Volltextzugriff (PDF)

A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance

Journal of medicinal chemistry, 2023-03, Vol.66 (6), p.4045-4058

2023

Volltextzugriff (PDF)

A ROS‐Responsive Liposomal Composite Hydrogel Integrating Improved Mitochondrial Function and Pro‐Angiogenesis for Efficient Treatment of Myocardial Infarction

Advanced healthcare materials, 2022-10, Vol.11 (19), p.e2200990-n/a

2022

Volltextzugriff (PDF)

HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis

Journal of pharmacy and pharmacology, 2020-11, Vol.72 (11), p.1564-1573

2020

Volltextzugriff (PDF)

Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease

Journal of medicinal chemistry, 2023-05, Vol.66 (9), p.6082-6104

2023

Volltextzugriff (PDF)

Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents

Bioorganic chemistry, 2019-11, Vol.92, p.103254-103254, Article 103254

2019

Volltextzugriff (PDF)

Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents

European journal of medicinal chemistry, 2022-02, Vol.229, p.114061, Article 114061

2022

Volltextzugriff (PDF)

Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease

Bioorganic chemistry, 2020-06, Vol.99, p.103803, Article 103803

2020

Volltextzugriff (PDF)

Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold

Bioorganic chemistry, 2019-11, Vol.92, p.103209-103209, Article 103209

2019

Volltextzugriff (PDF)

Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM

Bioorganic chemistry, 2020-08, Vol.101, p.103963-103963, Article 103963

2020

Volltextzugriff (PDF)

Discovery of a novel and orally active Farnesoid X receptor agonist for the protection of acetaminophen‐induced hepatotoxicity

Chemical biology & drug design, 2022-03, Vol.99 (3), p.483-495

2022

Volltextzugriff (PDF)

Discovery of Novel G‐Protein‐Coupled Receptor 40 Agonist with Phenylacetic Acid Scaffold for the Treatment of Type 2 Diabetes

ChemistrySelect (Weinheim), 2021-08, Vol.6 (29), p.7372-7375

2021

Volltextzugriff (PDF)

Renal protection of HWL-088 and ZLY032, two dual GPR40/PPARδ agonists, in adenine-induced renal fibrosis model

Chemistry & biodiversity, 2024-10, p.e202401598

2024

Volltextzugriff (PDF)

1 – 25 von 158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(143)

Publikationsform

Sprache

Englisch
(156)
Chinesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(116)
Life Sciences & Biomedicine
(52)
Technology
(49)
Physical Sciences
(45)
Chemistry
(40)
Materials Science
(27)
Engineering
(22)
Humans
(21)
Animals
(18)
Materials Science, Multidisciplinary
(18)
Chemistry, Physical
(17)
Chemistry, Multidisciplinary
(16)
Pharmacology & Pharmacy
(16)
Photovoltaic Cells
(16)
Male
(14)
Physics
(14)
Science & Technology - Other Topics
(14)
Mice
(13)
Biochemistry & Molecular Biology
(12)
Physics, Applied
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review

Enhancing fatigue properties of styrene butadiene rubber composites by improving interface adhesion between coated aramid fibers and matrix

Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents

HWL‐088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob/ob diabetic mice

Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ

Reinforcing effect of aramid fibers on fatigue behavior of SBR/aramid fiber composites

Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

ZLY032, the first-in-class dual FFA1/PPARδ agonist, improves glucolipid metabolism and alleviates hepatic fibrosis

A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob/ob) mice

Fluorofenidone ameliorates cholestasis and fibrosis by inhibiting hepatic Erk/-Egr-1 signaling and Tgfβ1/Smad pathway in mice

Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis

Design, synthesis, and biological studies of novel 3-benzamidobenzoic acid derivatives as farnesoid X receptor partial agonist

A Clinically Translatable Ternary Platinum(IV) Prodrug for Synergistically Reversing Drug Resistance

A ROS‐Responsive Liposomal Composite Hydrogel Integrating Improved Mitochondrial Function and Pro‐Angiogenesis for Efficient Treatment of Myocardial Infarction

HWL-088, a new and highly effective FFA1/PPARδ dual agonist, attenuates nonalcoholic steatohepatitis by regulating lipid metabolism, inflammation and fibrosis

Discovery of the First-in-Class Intestinal Restricted FXR and FABP1 Dual Modulator ZLY28 for the Treatment of Nonalcoholic Fatty Liver Disease

Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents

Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents

Discovery of novel dual PPARα/δ agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease

Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold

Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM

Discovery of a novel and orally active Farnesoid X receptor agonist for the protection of acetaminophen‐induced hepatotoxicity

Discovery of Novel G‐Protein‐Coupled Receptor 40 Agonist with Phenylacetic Acid Scaffold for the Treatment of Type 2 Diabetes

Renal protection of HWL-088 and ZLY032, two dual GPR40/PPARδ agonists, in adenine-induced renal fibrosis model

Suchergebnisse filtern